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journal.publications.chestneBACKGROUND: Bronchial epithelial ciliary dysfunction is an important feature of asthma. We
sought to determine the role in asthma of neutrophilic inﬂammation and nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases in ciliary dysfunction.
METHODS: Bronchial epithelial ciliary function was assessed by using video microscopy in
fresh ex vivo epithelial strips from patients with asthma stratiﬁed according to their sputum
cell differentials and in culture specimens from healthy control subjects and patients with
asthma. Bronchial epithelial oxidative damage was determined by 8-oxo-dG expression.
Nicotinamide adenine dinucleotide phosphate oxidase (NOX)/dual oxidase (DUOX)
expression was assessed in bronchial epithelial cells by using microarrays, with NOX4 and
DUOX1/2 expression assessed in bronchial biopsy specimens. Ciliary dysfunction following
NADPH oxidase inhibition, using GKT137831, was evaluated in fresh epithelial strips from
patients with asthma and a murine model of ovalbumin sensitization and challenge.
RESULTS: Ciliary beat frequency was impaired in patients with asthma with sputum
neutrophilia (n ¼ 11) vs those without (n ¼ 10) (5.8 [0.6] Hz vs 8.8 [0.5] Hz; P ¼ .003) and
was correlated with sputum neutrophil count (r ¼ –0.70; P < .001). Primary bronchial
epithelial cells expressed DUOX1/2 and NOX4. Levels of 8-oxo-dG and NOX4 were elevated
in patients with neutrophilic vs nonneutrophilic asthma, DUOX1 was elevated in both, and
DUOX2 was elevated in nonneutrophilic asthma in vivo. In primary epithelial cultures,
ciliary dysfunction did not persist, although NOX4 expression and reactive oxygen species
generation was increased from patients with neutrophilic asthma. GKT137831 both
improved ciliary function in ex vivo epithelial strips (n ¼ 13), relative to the intensity of
neutrophilic inﬂammation, and abolished ciliary dysfunction in the murine asthma model
with no reduction in inﬂammation.
CONCLUSIONS: Ciliary dysfunction is increased in neutrophilic asthma associated with
increased NOX4 expression and is attenuated by NADPH oxidase inhibition.
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Normal mucociliary clearance is essential in pulmonary
defense.1 Abnormal mucociliary clearance is a feature of
asthma, particularly in severe disease, as a consequence
of ciliary dysfunction.2 This ciliary dysfunction might
contribute to the persistent inﬂammation and
susceptibility to infection in the asthmatic airway, as
evidenced by higher bacterial DNA level3,4 and fungal
colonization, in particular Aspergillus fumigatus.5
Importantly, asthma is a heterogeneous disease and in
addition to the Th2-mediated eosinophilic paradigm,
neutrophilic-predominant inﬂammation is a feature
of one third of patients with asthma.6-9 Although the
cause of neutrophilic asthma is unclear, it is associated
with increased presence of proinﬂammatory and
Th1 cytokines in sputum and bacterial colonization.10
Pathogens can exert direct toxic effects on ciliary
function or indirectly via oxidative stress,11 and stimuli
such as infection,12 pollutants13 and proinﬂammatory
mediators14 can induce production of reactive oxygen
species (ROS). The nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (NOX)/dual oxidase
(DUOX) family plays an important role in the
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1446 Original ResearchNOX1-5 and DUOX1/2.15 DUOX expression in the
bronchial epithelium has been reported,16-18 and
DUOXs have been shown to be important for neutrophil
recruitment to the airways.19 In addition, we have
previously reported that NOX4 expression was
increased in airway smooth muscle in asthma, leading
to increased ROS production and intrinsic airway
smooth muscle hypercontractility.20 Whether NOX/
DUOX expression is altered in the bronchial
epithelium and possibly contributes to an increased
susceptibility to ciliary dysfunction in asthma is
unknown.
We hypothesized that ciliary dysfunction in asthma is
due to a combination of an intrinsic abnormality in
ciliary function and airway inﬂammation. To test our
hypothesis, we assessed: (1) the ciliary beat frequency
(CBF) in fresh ex vivo epithelial cells from patients with
asthma with and without sputum neutrophilia, (2) the
role of NADPH oxidases in ciliary function and their
speciﬁcity to the neutrophilic asthma phenotype, and (3)
the effects of NADPH oxidase inhibition on ciliary
function in a murine in vivo ovalbumin (OVA)
sensitization and challenge model.Methods
A more detailed description of the methods is available in e-Appendix 1.
Subjects
Patients with asthma and healthy control subjects were recruited from
a single center (Glenﬁeld Hospital). Asthma severity was deﬁned by
using the Global Initiative for Asthma (GINA) treatment steps (mildto moderate asthma, GINA steps 1-3; severe asthma, GINA steps
4-5).21 The study was approved by the Leicestershire Ethics
Committee (UHL 10613), and patients gave their written informed
consent.
Epithelial Cells
Primary epithelial cells were isolated from bronchial brushes during
bronchoscopy. Experiments were undertaken by using epithelial
human bronchial epithelial cells, characterized by cytokeratin 5 and
14 (Abcam) expression.22 Ciliary function was assessed in ciliated
air-liquid interface (ALI) cultures or fresh epithelial strips by using
video microscopy as previously described.23,24
Immunohistochemistry and Immunoﬂuorescence
Human bronchial biopsy specimens were embedded in
glycomethacrylate.20 Sections were stained by using an 8-oxo-dG
monoclonal antibody, anti-NADPH oxidase 4 antibody (Abcam),
anti-DUOX1 (Abcam), and anti-DUOX2 (Millipore) or
corresponding isotype control (DAKO and ImmunoStep). Staining
intensity above isotype control for 8-oxo-dG expression was assessed
by using a semiquantitative scoring ranging from none to low,
moderate, or high staining (0-3). For NOX4 and DUOX1/2, staining
intensity was measured in all areas of epithelium by thresholding
using Cell^F software (Olympus). All assessments were made by an
observer blinded to the subjects’ clinical characteristics. Cytospins of
human bronchial epithelial cells were labeled with polyclonal rabbit
antibodies to NOX1 and NOX4 (4 mg/mL, Insight Biotechnology;
4 mg/mL, Abcam, respectively) or the corresponding isotype control
(BD Bioscience). They were indirectly labeled with an
R-Phycoerythrin-conjugated secondary antibody (AbD Serotec). Cells
were counterstained with 40 ,60-diamidino-2 phenylindole (1 mg/mL;
Sigma-Aldrich).[ 1 4 9 # 6 CHES T J U N E 2 0 1 6 ]
RNA Extraction, Real-Time Quantitative Polymerase Chain
Reaction, and Gene Array
Total RNA was extracted from epithelial ALI cultures by using an
RNeasy Mini Kit with DNase I treatment (Qiagen). Complementary
DNA synthesis and quantitative polymerase chain reaction were
performed with a two-step real-time quantitative polymerase chain
reaction kit (Invitrogen) by using the Chromo4 Real-Time Detector
and Opticon Monitor 3 (Bio-Rad Laboratories). The internal
normalizer gene was 18S RNA ampliﬁed with 18S primer forward
(h18SRNA.891F:GTTGGTTTTCGGAACTGAGG) and 18S reverse
primer (h18SRNA.1090R:GCATCGTTTATGGTCGGAAC); ampliﬁcation
of NOX4 was with primers forward (hNox4.598F:TGGCT
GCCCATCTGGTGAATG) and reverse (hNox4.878R:CAGCA
GCCCTCCTGAAACATGC). Primers (Operon MWG Biotech) and
reaction mix (Invitrogen) were used as described previously.20
Relative quantiﬁcation of NOX4 messenger RNA (mRNA) was
performed by using the comparative 2DDCt method and expressed
as fold-change. The internal normalizer gene was 18S RNA.
RNA expression levels from basal epithelial cells were examined by
using the Human Genome U133A probe array (GeneChip;
Affymetrix). Hybridized biotinylated complementary RNA was
stained with streptavidin phycoerythrin (Molecular Probes), scanned
with a HP GeneArray Scanner (Hewlett-Packard). Image data from
each microarray were individually scaled to an intensity of 200 by
using GeneChip Operating Software (Affymetrix). Scaled average
differences and absolute call data were exported to text ﬁles for
further analysis.
Intracellular ROS Assay
Intracellular ROS generation in human bronchial epithelial cells was
quantiﬁed by using 5-(and-6)-carboxy-20 , 70-dichloroﬂuorescein
diacetate oxidation.20journal.publications.chestnet.orgIn Vivo Model of OVA Sensitization and Challenge
In a standard murine model of OVA sensitization and challenge
protocol that was adapted from Caceres et al,25 airway inﬂammation,
remodeling, and ciliary function were assessed. The University of
Leicester Ethics Committee and the UK Home Ofﬁce approved the
experimental protocols.NOX1/4 Inhibitor GKT137831
To investigate the effects of NADPH oxidase inhibition in asthmatic
epithelial cells and a murine model, we used GKT137831
(Genkyotex),26 a NADPH oxidase inhibitor that is selective for
NOX1 and NOX4 vs NOX2, NOX3, and NOX5. GKT137831
has greater selectivity and potency for NOX4 than for NOX1.
Its potential inhibitory effects on DUOX1/2 have not been fully
explored.Statistical Analysis
Statistical analyses were performed by using PRISM version 6
(GraphPad Software). Parametric data were described as mean 
SEM; geometric mean  95% conﬁdence intervals (CIs) were used
for log normally distributed data, and nonparametric data are
presented as median  interquartile range. Comparisons between
groups were assessed by using t tests (Mann-Whitney U test for
nonparametric data). Comparisons across $ 3 groups were analyzed
by using an analysis of variance (ANOVA) model (Kruskal-Wallis
test for nonparametric data) with post hoc pairwise comparisons
with the Tukey test (the Dunn test for nonparametric analyses).
Sputum eosinophil (> 3%) and neutrophil (> 61%) counts were
used as cutoffs to deﬁne inﬂammatory asthma phenotypes.27
Statistical analyses were performed as indicated in the ﬁgure legends,
and P < .05 was taken as the level of statistical signiﬁcance.Results
Clinical characteristics of the subjects who provided
bronchial biopsy specimens for immunohistochemistry
or epithelial brushings for ex vivo bronchial epithelial
strips are shown Table 1.
CBF was reduced in patients with neutrophilic
vs nonneutrophilic asthma (mean difference  95% CIs,
–2.97  0.87; P ¼ .003) (Fig 1A) and was correlated
with the percent sputum neutrophil count (r ¼ –0.70;
P < .001) (Fig 1B). Compared with our previously
published CBF in healthy control subjects
(10.7  0.4 Hz),2 CBF was reduced in those patients
with asthma with sputum neutrophilia (5.8  0.6 Hz;
P < .0001) but not in those without sputum neutrophilia
(8.8  0.5 Hz; P ¼ .089). There was no relationship
between sputum eosinophil count and CBF (r ¼ 0.19;
P ¼ .40) (Fig 1C).
Oxidative stress-induced DNA damage, represented by
semiquantitative assessment of 8-oxo-dG expression,
was increased in the bronchial epithelium in patients
with neutrophilic asthma (Kruskal-Wallis test, P ¼ .005)
(Figs 2A, 2B) and in those with severe disease vs mildto moderate disease and healthy control subjects
(Kruskal-Wallis test, P ¼ .036; data not shown). The
intensity of bronchial epithelial 8-oxo-dG expression
was also correlated to airﬂow obstruction (rs ¼ –0.68;
P < .001) (Fig 2C) and the percentage of sputum
neutrophils (rs ¼ 0.48; P ¼ .02) (Fig 2D).
Gene array analysis revealed the presence of NOX4 and
DUOX1 and DUOX2 expression, but not the other
NOX family members, in primary basal epithelial cells
from $ 3 of the six donors with asthma. There was
no signiﬁcant difference in the proportion of healthy
vs asthmatic donors who expressed NOX4, DUOX1,
or DUOX 2, and their relative expression was not
signiﬁcantly different between cells from patients with
asthma vs healthy control subjects (NOX4, 1.6-fold
[0.79-3.1]; DUOX1, 0.87-fold [0.46-1.63]; and DUOX2,
1.12-fold [0.38-3.3]). The geometric mean (95% CI)
percent b-actin expression was 0.07% (0.05-0.12)
for NOX4, 0.69% (0.56-0.95) for DUOX1, and
0.45% (0.06-1.3) for DUOX2. We therefore focused
our immunohistochemical analysis of bronchial
biopsy specimens on NOX4 and DUOX1/2.1447
TABLE 1 ] Clinical Characteristics of Subjects Who Provided Bronchial Epithelial Cells for Ex Vivo Studies or Bronchial Biopsy Sampling
Characteristic
Ex Vivo Epithelial Cell Donors Bronchial Biopsy Sample Donors
Healthy Control
(n ¼ 8)
Neutrophilic
(n ¼ 11)
Nonneutrophilic
(n ¼ 10)
Healthy Control
(n ¼ 17)
Neutrophilic Asthma
(n ¼ 20)
Nonneutrophilic Asthma
(n ¼ 20)
Sex (male/female) 5/3 7/4 7/3 12/5 12/8 5/15
Age, y 52  6 58  4 57  3 46  4 55  2 49  3
Current/ex-/never smoker 0/4/4 0/4/7 0/2/10 0/1/16 0/2/18 0/0/20
Pack-yearsa 8  5 3  2 1  1 0 (0-1) 0 (0-4) 0 (0-0)
Predicted FEV1, % 96  4 80  7 82  6 96  4 82  5 79  6
FEV1/FVC, % 78  2 59  5 62  5 78  2 67  3 69  3
Blood total IgE, kU/mLa NA 139 (68-438) 172 (122-665) NA 204 (36-1318) 243 (150-653)
Blood eosinophils, kU/mLa NA 0.22 (0.14-0.56) 0.28 (0.19-0.40) NA 0.47 (0.17-0.55) 0.23 (0.17-0.58)
Treatment (mg/24 BDP)a,b NA 1,000 (800-2,000) 1,600 (750-2,000) NA 1,600 (1,200-2,000) 1,600 (1,600-2,000)
GINA treatment step (1-3 or 4/5) NA 4, 7 1, 9 NA 5, 15 8, 12
No. with atopy NA 5 7 NA 15 16
Age of disease onset, y NA 38  7 26  5 NA 22  8 25  6
Sputum characterization
Eosinophils, %a NA 3.5 (1.3-22.5) 15.2 (3.8-36.5) NA 2.0 (0.3-5.2) 9.0 (0.4-23.7)
Neutrophils, %a NA 80.0 (65.0-87.2) 37.2 (3.8-36.5) NA 76.7 (67.9-85.8) 35.8 (20.0-46.5)
Data are presented as mean  SD unless otherwise indicated. GINA ¼ Global Initiative for Asthma; IgE ¼ immunoglobulin E; NA ¼ not applicable.
aMedian (interquartile range).
bBeclomethasone dipropionate (BDP) equivalence.
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Figure 1 – A-C, Baseline ciliary function of ciliated fresh ex vivo
bronchial epithelial strips. (A) CBF was measured in fresh ex vivo
epithelial strips from 10 patients with nonneutrophilic asthma and
11 patients with neutrophilic asthma. Comparisons were made by
using unpaired t tests. (B) Correlation between CBF of the fresh
ex vivo epithelial strips and sputum neutrophil count (n ¼ 21).
Patients with asthma with or without sputum neutrophilia (> 61%)
are represented as triangles or squares, respectively. (C) The CBF of
the fresh ex vivo epithelial strips and sputum eosinophil count is not
correlated (n ¼ 21). CBF ¼ ciliary beat frequency.
journal.publications.chestnet.orgNOX4 protein expression in epithelial cells of tissue
bronchial biopsy specimens was signiﬁcantly increased
in patients with neutrophilic asthma (29.5%  3.7%)
compared with patients with nonneutrophilic asthma
(18.5%  3.2%; P ¼ .041) and with healthy control
subjects (18.6%  2.9%; P ¼ .032) (ANOVA, P ¼ .040)
(Figs 3A, 3C), and it was signiﬁcantly correlated with
sputum neutrophil count (r ¼ 0.52; P ¼.042) but not
with lung function. DUOX1 protein expression was
increased in the epithelium in patients with
nonneutrophilic (29.0%  7.4%) and neutrophilic
(22.3%  4.7%) asthma vs healthy control subjects
(9.8%  3.2%; P ¼ .026 and P ¼ .041, respectively);
it was not differentially expressed in neutrophilic
vs nonneutrophilic phenotypes (P ¼ .465) (ANOVA,
P ¼ .048) (Figs 3B, 3D) and did not correlate with
sputum neutrophil count (r ¼ –0.06; P ¼ .832).
Although DUOX2 was expressed in a much lower
percentage of epithelium, a signiﬁcant increase was
seen in patients with nonneutrophilic asthma
(0.97%  0.29%; P ¼ .026) but not neutrophilic asthma
(0.58% 0.15%; P¼ .072) compared with healthy control
subjects (0.27% 0.07%), and expression was not
differentially expressed in neutrophilic vs nonneutrophilic
phenotypes (P ¼ .258) (ANOVA, P ¼ .045) (e-Fig 1).
NOX4 mRNA in epithelial ALI cultures was signiﬁcantly
increased in neutrophilic asthma samples compared
with healthy control samples (P ¼ .009) and
nonneutrophilic asthma samples (P ¼ .0061) (ANOVA,
P ¼ .004) (Fig 3E). NOX4 mRNA expression, as with
DNA damage, was correlated to airﬂow obstruction
(r ¼ –0.54; P ¼ .039) (Fig 3F). In basal epithelial cells,
NOX4 mRNA expression was similarly elevated,
although not signiﬁcantly, in the neutrophilic subtype
compared with the health and the nonneutrophilic
subtype (data not shown). At the protein level, basal
epithelial cells expressed NOX4 by immunoﬂuorescence
(Fig 3G) but not NOX1 (data not shown).
Baseline ROS production did not differ between health
and nonneutrophilic or neutrophilic asthma. However,
ROS-induced ROS production in response to H202
stimulation increased in neutrophilic asthma compared
with health and nonneutrophilic asthma as the
concentration of H202 increased. Indeed, the maximal
H2O2-induced intracellular ROS generation in basal
epithelial cells was signiﬁcantly increased in patients
with neutrophilic asthma (mean  SEM optical density,1449
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Figure 2 – A-D, Oxidative damage (8-oxo-dG levels) in human bronchial epithelium in vivo. (A) Representative photomicrographs showing 8-oxo-dG
staining in the epithelium in bronchial biopsy specimens from isotype control subjects (i); from a patient with asthma with positive staining of medium
intensity (ii) and high intensity (iii) (400). (B) Expression of 8-oxo-dG using a semiquantitative score (0 ¼ none, 1 ¼ low, 2 ¼ moderate, 3 ¼ high
expression) in healthy control subjects (circles) and in patients with asthma with or without sputum neutrophilia (> 61%) (triangles or squares,
respectively). Horizontal bars represent medians. Kruskal-Wallis test, P ¼ .005. (C) and (D) Correlation of the expression of 8-oxo-dG with airﬂow
obstruction and sputum neutrophil count, respectively (Spearman correlations are as shown).OD arbitrary units) (3,380  270) compared with health
(2,371  252; P ¼ .02) but not signiﬁcantly increased
compared with patients with nonneutrophilic asthma
(2,542 398; P¼ .11) (ANOVA, P¼ .037) (Figs 4A, 4B).1450 Original ResearchThe response to this maximum dose demonstrated a
trend to a correlation in the percentage of sputum
neutrophils (r ¼ 0.4; P ¼ .052). GKT137831 at 20 mM
(Genkyotex) signiﬁcantly reduced H2O2-induced[ 1 4 9 # 6 CHES T J U N E 2 0 1 6 ]
(10 mM) intracellular ROS generation, in health from
1,849  281 to 826  194 (mean difference [95% CI],
1022 [–1407 to –638]; P ¼ .001), and in asthma from
2,356  246 to 1,247  134 (–1,130 [–1,429 to –830];
P ¼ .0002) (Fig 4C). GKT137831 similarly attenuated
1 mM H2O2-induced ROS generation. In patients with
asthma, this reduction by GKT137831 (–1,362  105)
was greater than with N-acetylcysteine (5 mM)
(–1,044  90) (mean difference [95% CI], –318
[–626 to –10]; P ¼ .04) (Fig 4D). The reduction in
H2O2-induced (10 mM or 1 mM) ROS generation in
response to GKT137831 or N-acetylcysteine was not
signiﬁcantly different between health and asthma.
CBF and pattern were assessed in primary ALI cultured
epithelial cells from subjects with and without asthma by
using high-speed video microscopy (Videos 1A-1D).
In contrast to our ex vivo observations, there was no
signiﬁcant difference in the mean  SEM CBF between
health and disease according to the scraping method
(difference between means, 0.12  1.4 Hz; P ¼ .93)
(Fig 5A) or the overhead viewing method (difference
between means, 0.80  1.40; P ¼ .57 [ﬁve healthy
control subjects and 20 patients with asthma]; data
not shown). There were no relationships with asthma
severity (data not shown) or sputum neutrophil count
(rs ¼ –0.32; P ¼ .34). Beat patterns were similar in
the healthy control and asthmatic groups, including
percentage of normal cilia (50  7% vs 40%  5%;
P ¼ .28) (Fig 5B), dyskinetic cilia (41%  7% vs 53% 
4%; P ¼ .15) (Fig 5C), and static cilia (9%  3% vs 7% 
2%; P ¼ .58) (Fig 5D). These ﬁndings, together with
similar levels of ciliogenesis in culture between asthma
and health (60%  6% vs 63%  4%; P ¼ .72) and
surface morphology index (1.6  0.14 vs 1.7  0.12;
P ¼ .54), suggest the bronchial epithelial cells from
patients with asthma do not have a primary deﬁciency
in differentiation.
To further establish the role of NADPH oxidase in
ciliary dysfunction in asthma, we investigated the effect
of GKT137831 on ciliary function of fresh bronchial
epithelial strips studied within 1.5 h of bronchoscopy.
These experiments were performed without any
additional stimuli in contrast to the in vitro experiments
described earlier. Using these fresh samples from
patients with asthma, GKT137831 (5 mM and 20 mM)
signiﬁcantly increased CBF from baseline over the 1 h
of incubation. GKT137831 20 mM at 1 h resulted in
elevated CBF (10.9  0.6 Hz), signiﬁcantly different
from baseline (6.4  0.5 Hz) (mean difference [95% CI],
4.5 [3.5-5.5]; P < .0001) and from the diluent controlsjournal.publications.chestnet.org(8.9  0.9 Hz, 2.0 [0.6-3.4]; P ¼ .01) (Fig 6A). With
GKT137831 20 mM, the percentage of normal cilia
increased from 32%  5% to 48%  6% (mean
difference [95% CI], 16% [10-22]; P < .0001) at 0.5 h
and from 28%  5% to 45%  5% (mean difference
[95% CI], 17% [6-27]; P ¼ .01) at 1 h vs diluent (Fig 6B).
The percentage of dyskinetic cilia was reduced from
57%  4% to 50  5% (mean difference [95% CI],
–7% [–14 to 0.3]; P ¼ .04) at 0.5 h (Fig 6C) vs diluent.
This improvement in CBF in response to NADPH
oxidase inhibition was in fact due to cilia motility.
NADPH oxidase inhibition lowered the proportion of
static cilia compared with diluent, from 11%  4% to
2%  1% at 0.5 h (mean difference [95% CI], –9% [–16
to –2]; P ¼ .01) and from 17%  7% to 2%  1% at 1 h
(mean difference [95% CI], –15% [–29 to –0.6]; P ¼ .04)
(Fig 6D). Sputum neutrophil count was correlated to
the GKT137831-induced reduction in the percentage
of static cilia (r ¼ 0.61; P ¼ .03) (Fig 6E). It was also
correlated to the percentage of normal cilia (r ¼ 0.55;
P ¼ 0.05 [data not shown]). These improvements
were signiﬁcantly different in patients with neutrophilic
vs nonneutrophilic asthma (Fig 6F).
In a murine model of OVA sensitization and challenge
with the use of a standard protocol (Fig 7A), there was
evidence of inﬂammation in the bronchoalveolar lavage,
which was predominantly neutrophilic (Fig 7B) as well
as ciliary dysfunction (Figs 7C, 7D). Administration
of GKT137831 following OVA sensitization resulted
in no signiﬁcant change in bronchoalveolar lavage
total inﬂammatory cell count (OVA sensitization
alone vs GKT137831 alone, 303 [243-660] cells vs 240
[14-413] cells; P ¼ .33) or cell differential. Following
sensitization and challenge with OVA, the CBF was
markedly impaired (P < .001 compared with baseline),
and the addition of GKT137831 improved this ﬁnding
almost back to baseline (P ¼ .003). Similarly, the
percentage of ciliated cells was reduced following
sensitization and challenge with OVA compared with
baseline (P ¼ .007) and was restored following the
addition of GKT137831 (P ¼ .024).
Discussion
To our knowledge, we report here for the ﬁrst time
that bronchial epithelial ciliary dysfunction in asthma
is related to neutrophilic inﬂammation. This ciliary
dysfunction, evident in vivo, does not persist in vitro,
suggesting that the asthmatic airway environment is
essential in the development and maintenance of
ciliary dysfunction. In contrast to DUOX1, which was1451
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intracellular ROS, induced by H2O2, in human bronchial epithelial cells from healthy control subjects (n ¼ 8; circles), patients with nonneutrophilic
asthma (n ¼ 4; squares), and patients with neutrophilic asthma (n ¼ 9; triangles) quantiﬁed by using the 5-(and-6)-carboxy-20, 70-dichloroﬂuorescein
diacetate assay. (B) Corresponding maximum dose response for individual subjects. (C) The effect of GKT137831 on H2O2-induced intracellular ROS
generation in human bronchial epithelial cells from healthy control subjects (n ¼ 3; open bars) and patients with asthma (n ¼ 6; closed bars).
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(D) Reduction of H2O2 induced-intracellular ROS generation in response to GKT137831 (20 mM) and NAC (5 mM). Unpaired t test, P < .05.
EC50 ¼ half maximal effective concentration; NAC ¼ N-acetylcysteine; OD ¼ optical density; ROS ¼ reactive oxygen species.increased in asthma independent of inﬂammatory
phenotype, and DUOX2, which was only increased in
nonneutrophilic asthma, NOX4 expression was
upregulated only in the bronchial epithelium fromFigure 3 – A-G, Bronchial epithelial nicotinamide adenine dinucleotide pho
(A) Representative immunohistochemistry photomicrographs of (i) bronchial
protein expression in bronchial biopsy tissue from patients with (ii) nonneut
tochemistry photomicrographs of (i) bronchial biopsy specimens stained with
biopsy tissue from patients with (ii) nonneutrophilic and (iii) neutrophilic ast
by using thresholding and expressed as percent area of positive staining. Bar r
cultures, quantiﬁed by real-time quantitative polymerase chain reaction, in
asthma (n ¼ 4; squares), and patients with neutrophilic asthma (n ¼ 4; tria
(F) Correlation between NOX4 gene expression in air-liquid interface cultur
(G) Immunoﬂuorescence staining of cytospun basal epithelial cells for NOX4
control is shown as inset; 20 magniﬁcation, scale bar represents 50 mm. m
journal.publications.chestnet.orgpatients with asthma with neutrophilic inﬂammation
in vivo. This increased NOX4 expression was also
present in vitro with NADPH oxidase-dependent
increased ROS generation in primary epithelial cellssphate (NADPH) oxidase expression in asthma in vivo and in vitro.
biopsy specimen stained with an isotype control and epithelial NOX4
rophilic and (iii) neutrophilic asthma. (B) Representative immunohis-
an isotype control and epithelial DUOX1 protein expression in bronchial
hma. Intensity of staining of (C) NOX4 and (D) DUOX1 was measured
epresents mean (SEM). (E) NOX4 gene expression in air-liquid interface
healthy control subjects (n ¼ 7; circles), patients with nonneutrophilic
ngles). Analysis of variance and post hoc Tukey tests as shown.
es and airﬂow obstruction (Spearman correlation as shown).
. NOX4 is stained red, nuclei is stained blue, and the isotype
RNA ¼ messenger RNA.
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Figure 5 – A-D, Ciliary function of human primary bronchial epithelial cell cultures. (A) CBF of ciliated epithelial cells from healthy control
subjects (circles), patients with nonneutrophilic asthma (squares), and patients with neutrophilic asthma (triangles). Ciliary beat patterns were
expressed in the percentage of (B) normally beating cilia, (C) dyskinetic cilia, and (D) static cilia. Unpaired t test, P values as shown. See Figure 1
legend for expansion of abbreviation.from patients with asthma with neutrophilic
inﬂammation. Critically, NADPH oxidase inhibition
completely abrogated ciliary dysfunction in ex vivo
epithelial strips, as evidenced by restoration of CBF to
the frequency we previously described in epithelial strips
from healthy subjects2 and in an in vivo murine model
of asthma with evidence of neutrophilic lung inﬂammation,
but it did not signiﬁcantly reduce this inﬂammation.
Taken together, these ﬁndings support the view that
ciliary dysfunction in asthma is both NADPH oxidase-
dependent (in particular NOX4) and inﬂammation-
dependent, with both necessary but neither sufﬁcient, as
persistent ciliary dysfunction was not observed in vitro
despite increased NOX4 expression, and NADPH oxidase
inhibition abolished ciliary dysfunction without affecting
airway inﬂammation.
Noneosinophilic, and speciﬁcally neutrophilic, asthma
is common9 but responds poorly to corticosteroid
therapy.7 Neither the mechanisms nor the clinical
management of neutrophilic asthma are fully1454 Original Researchunderstood. Oxidative stress and neutrophilia are often
associated,14 and, consistent with this view, we found
that neutrophilic asthma and airﬂow obstruction were
associated with oxidative DNA damage, as evidenced
by increased bronchial epithelial 8-oxo-dG expression
assessed semiquantitatively. Critically, we extended our
earlier observation that ciliary dysfunction is impaired
in asthma and associated with increasing severity2 to
demonstrate that this ciliary dysfunction is a particular
feature of neutrophilic asthma. Normal ciliary function
is a key component of innate immunity, and its
impairment is likely to promote persistence of
inﬂammation and increase risk of airway infection
and colonization by pathogens.3,4,10 Indeed, macrolide
antibiotics have demonstrated efﬁcacy in noneosinophilic
asthma,28 but concerns related to antibiotic resistance
as a consequence of long-term widespread antibiotic
use highlight the need for new therapies to treat
neutrophilic asthma. The biologic relevance of the
magnitude of CBF changes we observed in fresh
bronchial strips following GKT137831 treatment must[ 1 4 9 # 6 CHES T J U N E 2 0 1 6 ]
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exposure to GKT137831, the CBF in the patients with
asthma improved to a level we have reported previously
in health2 and the improvement above diluent (2 Hz)
was similar to the differences observed between health
and COPD.29
NADPH oxidases play a critical role in ROS generation.
NOX4 and DUOX1/2 expression in the epithelium was
evident in asthma. DUOX1 was increased in asthma
independent of inﬂammatory phenotype, and DUOX2
was only increased in nonneutrophilic asthma. In
contrast, NOX4 was only increased in neutrophilic
asthma. NOX4 plays a crucial role in regulating altered
oxidative pathways in idiopathic pulmonary ﬁbrosis30-32
and several nonrespiratory diseases,26,33,34 and its
expression is upregulated by oxidative stress itself and
inﬂammation. We found that increased ROS in the
bronchial epithelium was a feature of neutrophilic1456 Original Researchasthma that persisted in vitro in association with
increased NOX4 expression. Although NOX4 might
be upregulated by neutrophilic inﬂammation, its
overexpression can occur independently of the
asthmatic environment. Importantly, ciliary dysfunction
did not persist in vitro, suggesting this NOX4
upregulation was not itself sufﬁcient to drive ciliary
dysfunction but also required the presence of airway
inﬂammation.
Beyond asthma, bronchial epithelial ciliary dysfunction
is a fundamental abnormality in bronchiectasis,35
as well as in COPD.36 Antioxidant therapy, such as
N-acetylcysteine, has been considered in these
conditions; however, studies are inconsistent with
beneﬁts demonstrated in some studies37 but not in
others.38,39 The magnitude of beneﬁt is also relatively
small, possibly due to poor tolerance of high
concentrations of the therapeutic agent, questionable[ 1 4 9 # 6 CHES T J U N E 2 0 1 6 ]
bioavailability, and use of nonspeciﬁc antioxidant
therapies that enhance the clearance of ROS rather than
targeting ROS generation. Our ﬁndings suggest that
NAPDH oxidase inhibition, which reduces intracellular
ROS generation, improves ciliary dysfunction and thus
extends the potential role of NADPH oxidases (and
particularly NOX4) in asthma beyond the described
impact of upregulated NOX4 on airway smooth muscle
hypercontractility.20
A major limitation of our study is that although
GKT137831 has good speciﬁcity and potency for NOX4,
it also has effects on NOX1 and is likely to exert effects
on DUOX, as has been observed with similar inhibitors
in this class (eg, GKT136901).40 Our ﬁndings support
a key role for NOX4; the expression of this NOX
family member was increased in neutrophilic asthma
and associated with ciliary dysfunction. However, we
cannot fully exclude possible contributions from other
mechanisms, including other members of the NOX
family (particularly DUOX1/2). In addition, due to the
considerable homology in the amino acid sequence of
DUOX1 and DUOX2, the DUOX2 antibody may
cross-react with DUOX1. However the amount of
staining seen with the DUOX2 antibody is considerably
less than that with the DUOX1 antibody. Thus, we are
conﬁdent that DUOX2 is not highly expressed in the
bronchial epithelium. One further potential limitation
of our study is the lack of direct in vivo human datajournal.publications.chestnet.orgdemonstrating that NADPH oxidase inhibition modiﬁes
ciliary function and inﬂammation. However, we have
conﬁrmed the importance of NADPH oxidase in ciliary
dysfunction in fresh ex vivo primary cells studied
immediately after obtaining the cells at bronchoscopy,
and we supported the observations by using an
in vivo murine model of asthma with neutrophilic
lung inﬂammation. This asthma model clearly showed
that NADPH oxidase inhibition markedly improved
ciliary function but did not signiﬁcantly attenuate lung
inﬂammation. These ﬁndings suggest that although the
presence of inﬂammation might be important for NOX4
activation, it is the consequent ROS generation rather
than the inﬂammation per se that is critical in ciliary
dysfunction.Conclusions
Bronchial epithelial cells from patients with asthma
with neutrophilic airway inﬂammation exhibit
heightened NOX4 expression and ROS generation.
NADPH oxidase inhibition in an in vivo murine model
of asthma improved ciliary function, which was also
conﬁrmed in ex vivo bronchial epithelial cells from
patients with neutrophilic asthma. These ﬁndings
support the view that NADPH oxidase inhibition
(and in particular NOX4) might present a new stratiﬁed
approach for the treatment of neutrophilic asthma.1457
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